Vivox

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

48 API Suppliers, 20 USDMF, 11 CEP/COS, 1 JDMF, 2 EU WC, 2 KDMF, 14 NDC API, 1 VMF, 21 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

41 Drugs in Development

41 Drugs in Development

FINISHED DOSAGE FORMULATIONS

236 FDF Dossiers, 186 FDA Orange Book, 11 Europe, 15 Canada, 24 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 150MG BASE, TABLET;ORAL - EQ 75MG BASE, TABLET;ORAL - EQ 100MG BASE, CAPSULE;ORAL - EQ 100MG BASE, CAPSULE;ORAL - EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, CAPSULE, DELAYED RELEASE;ORAL - EQ 100MG BASE, CAPSULE, DELAYED RELEASE;ORAL - EQ 75MG BASE, SYSTEM, EXTENDED RELEASE;PERIODONTAL - 50MG, TABLET, DELAYED RELEASE;ORAL - EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, DELAYED RELEASE;ORAL - EQ 120MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, DELAYED RELEASE;ORAL - EQ 150MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, DELAYED RELEASE;ORAL - EQ 200MG BASE, TABLET, DELAYED RELEASE;ORAL - EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, DELAYED RELEASE;ORAL - EQ 60MG BASE, TABLET, DELAYED RELEASE;ORAL - EQ 75MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, DELAYED RELEASE;ORAL - EQ 80MG BASE

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 3 Rochem International Inc, 18 SPI Pharma, 12 DKSH, 8 Boai NKY Pharmaceuticals Ltd, 7 Gangwal Healthcare, 7 Nanjing Well Pharmaceutical, 2 Pfanstiehl, 6 Kirsch Pharma, 4 ACG Worldwide, 12 Actylis, 2 Aeon Procare, 1 Alcedo Pharmachem, 9 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 3 Ashland, 33 BASF, 1 CD Formulation, 1 Clariant, 11 Corel Pharma Chem, 7 DFE Pharma, 1 Esteem Industries, 3 Finar, 12 Gangwal Chemicals, 6 Ideal Cures, 5 Ingredion Pharma Solutions, 27 Kerry, 4 Keval Exports, 5 Kima Chemical, 6 Lonza Capsugel, 22 Microlex e.U, 1 Nanjing Bold Chemical, 2 Nitika Pharmaceutical Specialities, 2 Nomisma Healthcare, 4 Novo Excipients, 4 Pharmatrans-Sanaq, 8 Pluviaendo, 4 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 29 Roquette, 14 Seppic, 8 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 2 Shijiazhuang Huaxu Pharmaceutical, 11 Sigachi Industries, 4 Silverline Chemicals, 4 The Dow Chemical Company, 2 Ulanqab Kema New Material, 1 Valens Pharmachem, 4 Vasa Pharmachem, 1 Vertellus, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

85 Fillers, Diluents & Binders, 60 Coating Systems & Additives, 45 Disintegrants & Superdisintegrants, 45 Thickeners and Stabilizers, 44 Direct Compression, 38 Granulation, 32 Parenteral, 30 Solubilizers, 29 Controlled & Modified Release, 27 Film Formers & Plasticizers, 25 Taste Masking, 21 Lubricants & Glidants, 21 Topical, 21 Chewable & Orodispersible Aids, 15 Co-Processed Excipients, 11 Rheology Modifiers, 9 Empty Capsules, 9 Emulsifying Agents, 7 API Stability Enhancers, 6 Surfactant & Foaming Agents, 5 Coloring Agents, 4 Vegetarian Capsules, 1 Soft Gelatin

DIGITAL CONTENT

51 News #PharmaBuzz

51 News #PharmaBuzz

GLOBAL SALES INFORMATION

38 US Medicaid Prescriptions, 18 Regulatory FDF Prices

MARKET PLACE

72 APIs, 1 FDF Dossiers

PATENTS & EXCLUSIVITIES

14 US Patents

14 US Patents

REF. STANDARDS & IMPURITIES

2 EDQM, 1 Others

$ Xls

Filters

Xls

USFDA APPLICATION NUMBER - 50795 / DOSAGE - TABLET, DELAYED RELEASE;ORAL - EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

Ingredient Name	Basis of Strength	Strength
Active Ingredient/Active Moiety
DOXYCYCLINE HYCLATE(UNII: 19XTS3T51U) (DOXYCYCLINE ANHYDROUS - UNII:334895S862)	DOXYCYCLINE ANHYDROUS	75mg in 100

Inactive Ingredients

Ingredient Name	Allergan, Inc.	Mayne Pharma International Pty Ltd
ANHYDROUS LACTOSE(3SY5LH9PMK)
CELLULOSE, MICROCRYSTALLINE(OP1R32D61U)
CROSPOVIDONE(2S7830E561)
CROSPOVIDONE(68401960MK)
LACTOSE MONOHYDRATE(EWQ57Q8I5X)
MAGNESIUM STEARATE(70097M6I30)
SODIUM CHLORIDE(451W47IQ8X)
SODIUM LAURYL SULFATE(368GB5141J)
STARCH, CORN(O8232NY3SJ)
TALC(7SEV7J4R1U)

Setid 4f6aae90 7acd 4ef3 8b6c 2115b63d507b Applno 50795 Form Tablet Delayed Release Oral Dosage Eq 50mg Base - Drug Product Composition: Vivox

Vivox

Vivox

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

48 API Suppliers

20 USDMF

11 CEP/COS

1 JDMF

2 EU WC

2 KDMF

14 NDC API

1 VMF

21 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

41 Drugs in Development

FINISHED DOSAGE FORMULATIONS

236 FDF Dossiers

186 FDA Orange Book

11 Europe

15 Canada

24 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 150MG BASE

TABLET;ORAL - EQ 75MG BASE

TABLET;ORAL - EQ 100MG BASE

CAPSULE;ORAL - EQ 100MG BASE

CAPSULE;ORAL - EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

CAPSULE, DELAYED RELEASE;ORAL - EQ 100MG BASE

CAPSULE, DELAYED RELEASE;ORAL - EQ 75MG BASE

SYSTEM, EXTENDED RELEASE;PERIODONTAL - 50MG

TABLET, DELAYED RELEASE;ORAL - EQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, DELAYED RELEASE;ORAL - EQ 120MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, DELAYED RELEASE;ORAL - EQ 150MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, DELAYED RELEASE;ORAL - EQ 200MG BASE

TABLET, DELAYED RELEASE;ORAL - EQ 50MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, DELAYED RELEASE;ORAL - EQ 60MG BASE

TABLET, DELAYED RELEASE;ORAL - EQ 75MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, DELAYED RELEASE;ORAL - EQ 80MG BASE

RELATED EXCIPIENT COMPANIES

2 EUROAPI

3 Rochem International Inc

18 SPI Pharma

12 DKSH

8 Boai NKY Pharmaceuticals Ltd

7 Gangwal Healthcare

7 Nanjing Well Pharmaceutical

2 Pfanstiehl

6 Kirsch Pharma

4 ACG Worldwide

12 Actylis

2 Aeon Procare

1 Alcedo Pharmachem

9 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

3 Ashland

33 BASF

1 CD Formulation

1 Clariant

11 Corel Pharma Chem

7 DFE Pharma

1 Esteem Industries

3 Finar

12 Gangwal Chemicals

6 Ideal Cures

5 Ingredion Pharma Solutions

27 Kerry

4 Keval Exports

5 Kima Chemical

6 Lonza Capsugel

22 Microlex e.U

1 Nanjing Bold Chemical

2 Nitika Pharmaceutical Specialities

2 Nomisma Healthcare

4 Novo Excipients

4 Pharmatrans-Sanaq

8 Pluviaendo

CAPSULE;ORAL - EQ 50MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, DELAYED RELEASE;ORAL - EQ 100MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, DELAYED RELEASE;ORAL - EQ 120MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, DELAYED RELEASE;ORAL - EQ 150MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, DELAYED RELEASE;ORAL - EQ 50MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, DELAYED RELEASE;ORAL - EQ 75MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons